Roger W. Byhardt

19.0k total citations · 7 hit papers
186 papers, 14.5k citations indexed

About

Roger W. Byhardt is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Roger W. Byhardt has authored 186 papers receiving a total of 14.5k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Pulmonary and Respiratory Medicine, 64 papers in Oncology and 39 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Roger W. Byhardt's work include Lung Cancer Treatments and Mutations (77 papers), Lung Cancer Diagnosis and Treatment (70 papers) and Lung Cancer Research Studies (38 papers). Roger W. Byhardt is often cited by papers focused on Lung Cancer Treatments and Mutations (77 papers), Lung Cancer Diagnosis and Treatment (70 papers) and Lung Cancer Research Studies (38 papers). Roger W. Byhardt collaborates with scholars based in United States, Canada and Puerto Rico. Roger W. Byhardt's co-authors include Sucha O. Asbell, James D. Cox, Arnold Herskovic, Jay S. Cooper, Muhyi Al‐Sarraf, Charles Scott, Todd H. Wasserman, Bahman Emami, Laurie E. Gaspar and Marvin Rotman and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Roger W. Byhardt

182 papers receiving 14.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials

1997 1.9k citations Charles Scott, Sucha O. Asbell et al. International Journal of Radiation Oncology*Biology*Physics profile →
Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus

1992 1.6k citations Arnold Herskovic, Karen Martz et al. New England Journal of Medicine profile →
Chemoradiotherapy of Locally Advanced Esophageal Cancer

1999 1.5k citations Jay S. Cooper, Arnold Herskovic et al. profile →
Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

2000 684 citations Roger W. Byhardt, Karen K. Fu et al. International Journal of Radiation Oncology*Biology*Physics profile →
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer

1995 541 citations Charles Scott, D. Johnson et al. JNCI Journal of the National Cancer Institute profile →
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study.

1997 525 citations Muhyi Al‐Sarraf, Karen Martz et al. Journal of Clinical Oncology profile →
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

1997 492 citations Richard Caplan, Roger W. Byhardt et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Roger W. Byhardt

Since Specialization

Citations

This map shows the geographic impact of Roger W. Byhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger W. Byhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger W. Byhardt more than expected).

Fields of papers citing papers by Roger W. Byhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger W. Byhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger W. Byhardt. The network helps show where Roger W. Byhardt may publish in the future.

Co-authorship network of co-authors of Roger W. Byhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Roger W. Byhardt. A scholar is included among the top collaborators of Roger W. Byhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger W. Byhardt. Roger W. Byhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02 2009 ·Clinical Cancer Research ·Alan Pollack, Kyounghwa Bae, Li‐Yan Khor, Tahseen Al‐Saleem, M. Elizabeth H. Hammond, Varagur Venkatesan, Roger W. Byhardt, Sucha O. Asbell, William U. Shipley, Howard M. Sandler	24
2	PD5-2-4: Phase I/II results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC 2007 ·Journal of Thoracic Oncology ·Jeffrey D. Bradley, Mary V. Graham, Jennifer Moughan, Roger W. Byhardt, Ramaswamy Govindan, Jack Fowler, James A. Purdy, Jeff M. Michalski, Elizabeth Gore, Hak Choy	3
3	Age Is Independent of Comorbidity Influencing Patient Selection for Combined Modality Therapy for Treatment of Stage III Nonsmall Cell Lung Cancer (NSCLC) 2006 ·American Journal of Clinical Oncology ·S. Firat, Adam Pleister, Roger W. Byhardt, Elizabeth Gore	45
4	Radiotherapy (RT) patterns of care study (PCS) in lung carcinoma 2002 ·International Journal of Radiation OncologyBiologyPhysics ·Benjamin Movsas, Jennifer Moughan, Ritsuko Komaki, H. Choy, Roger W. Byhardt, Corey J. Langer, MA Goldberg, Melanie L. Graham, David S. Ettinger, David W. Johnstone, R. A. Abrams, Reginald F. Munden, George Starkschall, Jean B. Owen	4
5	Androgen ablation adjuvant to defintive radiotherapy in carcinoma of the prostate: year 2000 update of RTOG phase III studies 86-10 and 85-31 2000 ·International Journal of Radiation OncologyBiologyPhysics ·M.V. Pilepich, (unknown), Roger W. Byhardt, J Mesić, Mitchell Machtay, Gerald E. Hanks, Majnu John, William T. Sause	7
6	Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 rtog patients 1999 ·International Journal of Radiation OncologyBiologyPhysics ·Maria Werner‐Wasik, Charles Scott, M.L. Graham, Colum J Smith, Roger W. Byhardt, Mack Roach, E. Andras	31
7	Impact of Adding Concurrent Chemotherapy to Hyperfractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC): 1997 ·American Journal of Clinical Oncology ·Ritsuko Komaki, Charles Scott, Jin S. Lee, Raul C. Urtasun, Roger W. Byhardt, Bahman Emami, E. Andras, (unknown), Marvin Rotman, James D. Cox	26
8	Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation therapy oncology group (RTOG) 92-04 1997 ·International Journal of Radiation OncologyBiologyPhysics ·Ritsuko Komaki, Charles L. Scott, David S. Ettinger, (unknown), (unknown), Walter Curran, Richard F. L. Evans, Philip Rubin, Roger W. Byhardt	74
9	Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in rtog 88-08/ECOG 4588 1997 ·International Journal of Radiation OncologyBiologyPhysics ·Ritsuko Komaki, Charles Scott, William T. Sause, David H. Johnson, Samuel G. Taylor, Jin S. Lee, Bahman Emami, Roger W. Byhardt, Walter J. Curran, (unknown), James D. Cox	105
10	Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. 1996 ·Journal of Clinical Oncology ·William Tester, Richard Caplan, John Heaney, Peter Venner, Richard Whittington, Roger W. Byhardt, Lawrence D. True, William U. Shipley	201
11	Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. 1996 ·Journal of Clinical Oncology ·Jack Lee, Charles Scott, Ritsuko Komaki, Frank V. Fossella, G. Dundas, Sandra McDonald, Roger W. Byhardt, W.J. Curran	141
12	Randomized phase trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: Results of RTOG 88-09 1995 ·International Journal of Radiation OncologyBiologyPhysics ·Karen K. Fu, (unknown), K. Kian Ang, Roger W. Byhardt, Moshe Maor, Jonathan J. Beitler	50
13	Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer breakdown → 1995 ·JNCI Journal of the National Cancer Institute ·(unknown), Charles Scott, (unknown), D. Johnson, R. Livingston, Ritsuko Komaki, B. Emami, Walter J. Curran, Roger W. Byhardt, (unknown), A. Rashid Dar, J.D. Cox	541
14	The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a radiation therapy oncology group (RTOG) protocol 1993 ·International Journal of Radiation OncologyBiologyPhysics ·Roger W. Byhardt, Linda Martin, Thomas F. Pajak, Kyu H. Shin, Bahman Emami, James D. Cox	71
15	A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: Report of radiation therapy oncology group 84-07 1993 ·International Journal of Radiation OncologyBiologyPhysics ·Roger W. Byhardt, Thomas F. Pajak, Bahman Emami, Arnold Herskovic, Reuben S. Doggett, (unknown)	41
16	Phase II Trial of Combination Chemotherapy and Irradiation in Non-Small-Cell Lung Cancer, Radiation Therapy Oncology Group 88–04 1992 ·American Journal of Clinical Oncology ·William T. Sause, Charles Scott, Samuel G. Taylor, Roger W. Byhardt, (unknown), John W. Thomson, Thomas K. Jones, Jay S. Cooper, Robert D. Lindberg	42
17	Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus breakdown → 1992 ·New England Journal of Medicine ·Arnold Herskovic, Karen Martz, Muhyi Al‐Sarraf, Lawrence Leichman, Jeffrey Brindle, Vainutis K. Vaitkevicius, Jay S. Cooper, Roger W. Byhardt, Lawrence P. Davis, Bahman Emami	1566
18	Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: Report of an rtog prospective randomized trial 1989 ·International Journal of Radiation OncologyBiologyPhysics ·Joseph R. Simpson, Madeline Bauer, (unknown), Todd H. Wasserman, Bahman Emami, (unknown), Roger W. Byhardt, Theodore L. Phillips, (unknown)	30
19	Thoracic irradiation with or without levamisole (NSC #177023) in unresectable non-small cell carcinoma of the lung: a phase III randomized trial of the RTOG 1988 ·International Journal of Radiation OncologyBiologyPhysics ·Carlos A. Pérez, Madeline Bauer, (unknown), Roger W. Byhardt, Luther W. Brady, R. L. Scotte Doggett, Patricia Gardner, M. Zinninger	25
20	Advanced carcinoma of the nasopharynx 1982 ·Radiology ·(unknown), James D. Cox, Bernard Roswit, (unknown), Robert Middleton, (unknown), (unknown), Roger W. Byhardt, Camilo Paig, Juan A. del Regato	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact